Status:

UNKNOWN

The Tracking Molecular Evolution for NSCLC (T-MENC) Study

Lead Sponsor:

Geneplus-Beijing Co. Ltd.

Collaborating Sponsors:

Xuanwu Hospital, Beijing

Conditions:

Lung Neoplasms

Lung Cancer

Eligibility:

All Genders

18-80 years

Brief Summary

Tumor genomic clonal evolution assessed with liquid biopsy of stage IB,II and IIIA non-small cell lung cancer patients after getting radical resection. Plasma circulating tumor DNA (ctDNA) analysis de...

Detailed Description

In the study, 200 of stage IB,II and IIIA non-small cell lung cancer patients obtained radical resection will be recruited. All the patients will receive biopsy genotype assay and ctDNA liquid biopsy....

Eligibility Criteria

Inclusion

  • Provision of informed consent and assigned.
  • Newly diagnosed and histological or cytological confirmed stage IB-IIIA lung adenocarcinoma or non-smoking squamous cell carcinoma patients according to the AJCC staging system.
  • Expected radical resection.
  • Patients expected more than 3 months of survival time.
  • Willingness to comply with required protocols and give permission to use the data for clinical research and products development.

Exclusion

  • Patients who want Neo-adjuvant therapy.
  • Patients with T3-4N1 Pancoast tumors (superior sulcal tumors).
  • Multi-station N2 non-small cell lung cancer with lymph node metastasis.
  • Eastern cooperative oncology group (ECOG) performance status \> 2 after postoperative chemotherapy
  • Eastern cooperative oncology group (ECOG) performance status \> 4 after postoperative targeted therapy.
  • Patients must never ever has received for any history of radiotherapy/ chemotherapy/surgery before.
  • Patients have other primary cancers.
  • Known central nervous system metastasis.
  • Patients expected less than 3 months of survival time.
  • Other situations mismatch this program.

Key Trial Info

Start Date :

November 6 2018

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2021

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT03838588

Start Date

November 6 2018

End Date

December 31 2021

Last Update

February 12 2019

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

Beijing Hospital

Beijing, Beijing Municipality, China, 100005

2

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China, 100021

3

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China, 100029

4

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China, 100050

The Tracking Molecular Evolution for NSCLC (T-MENC) Study | DecenTrialz